Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy.

Frontiers in immunology - 1 Jan 2021

Wang Shuhang, Fang Yuan, Jiang Ning, Xing Shujun, Li Qin, Chen Rongrong, Yi Xin, Zhang Zhiqian, Li Ning

Abstract excerpt

Treatment options for rare tumors are limited, and comprehensive genomic profiling may provide useful information for novel treatment strategies and improving outcomes. The aim of this study is to explore the treatment opportunities of patients with rare tumors using immune checkpoint inhibitors (ICIs) that have already been approved for routine treatment of common tumors. We collected immunotherapy-related...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to China
Share to Gene Expression Profiling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomics

Share to High-Throughput Nucleotide Sequencing

Share to Immunotherapy

Share to Neoplasms

Share to Rare Diseases

Source

Open in PubMed Open full text

Identifiers

PMID: 33732253
DOI: 10.3389/fimmu.2021.631483
PMCID: PMC7959707

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy.PMID 33732253Read ↗

First report: PLATFORM study for precision treatment of rare tumors in China.Semantic proximity Read ↗

Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours.Semantic proximity Read ↗

A Comprehensive Tumor Molecular Profile Analysis in Clinical Practice: A Single Center’s ExperienceSemantic proximity Read ↗

Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancerSemantic proximity Read ↗

Comprehensive analysis of potential immunotherapy genomic biomarkers in 1,000 Chinese patients with cancerSemantic proximity Read ↗

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.Semantic proximity Read ↗

Classification of tumor microenvironment immune types based on immune response-associated gene expressionSemantic proximity Read ↗

Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors.Semantic proximity Read ↗

Druggable gene alterations in Japanese patients with rare malignancy.Semantic proximity Read ↗

Comprehensive tumor molecular profile analysis in clinical practice.Semantic proximity Read ↗

A Multi-Omics Analysis of an Exhausted T Cells’ Molecular Signature in Pan-CancerSemantic proximity Read ↗

Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.